^
Association details:
| Biomarker: | ROR1 positive |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | LYL797 (ROR1-targeted CAR-T immunotherapy) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1118: Preclinical Development of LYL119, a ROR1-Targeted CAR T-Cell Product Candidate Incorporating Four Novel T-Cell Reprogramming Technologies to Overcome Barriers to Effective Cell Therapy for Solid Tumors
Published date:
05/02/2023
Excerpt:
The resulting ROR1-targeted CAR-T cell product, LYL119, combines these T-cell reprogramming technologies to create potent CAR T cells with durable function (Figure 1A)…We then evaluated combining Stim-R and Epi-R technologies for ROR1 CAR T production. These cells showed prolonged cytotoxicity and cytokine production in vitro, and significantly improved tumor control (p<0.0001), CAR T cell expansion in blood (31-fold, p<0.0001), and overall survival (p<0.0001) in the H1975 in vivo model...Together these data suggest that stacking these four technologies can limit exhaustion and has the potential to provide effective and durable ROR1 CAR T-cell functional activity in patients with ROR1+ solid tumor malignancies.
Source:
Title:
Preclinical Development of LYL797, a ROR1-Targeted CAR T-Cell Therapy Enhanced with Genetic and Epigenetic Reprogramming for Solid Tumors
Published date:
05/03/2022
Excerpt:
Additionally, LYL797 demonstrated overall improved survival and expansion in the peripheral blood of ROR1+ tumor-bearing animals, which correlated with improved anti-tumor activity in an established human ROR1+ NSCLC mouse xenograft model.
